Trump orders overhaul of pediatric vaccine schedule

Good morning, healthcare professional.

Federal vaccine policy faces a major shift as the Trump administration issues an executive order questioning childhood immunization schedules, while pharmaceutical M&A activity heats up with a billion-dollar rare disease acquisition. Clinical trial setbacks in cystic fibrosis and new FDA food safety regulations round out a day of significant regulatory and business developments.

These stories highlight the ongoing tension between public health policy and political pressures, the continued consolidation in specialty pharma, and regulators' expanding focus on transparency across the healthcare and food sectors.

In today's healthcare digest:

• Trump administration orders review of pediatric vaccine recommendations
• Jazz Pharmaceuticals pursues $1.3 billion acquisition in rare epilepsy space
• Sionna's experimental cystic fibrosis treatment fails Phase 2/3 trial
• FDA introduces first-ever notification requirement for food additives

Trump Administration Targets Childhood Vaccine Schedule

President Trump signed an executive order directing a comprehensive review of pediatric vaccine recommendations, marking a return to controversial vaccine policy positions. The order questions the current childhood immunization schedule maintained by the CDC's Advisory Committee on Immunization Practices.

Unpacked:

• The executive order represents a federal challenge to established vaccine schedules that have been standard practice for decades.
• Two major industry publications covered the development, signaling significant concern across healthcare and pharmaceutical sectors.
• The policy shift could affect vaccine manufacturers, pediatricians, and millions of families navigating childhood immunization decisions.

Jazz Pharmaceuticals Expands Rare Disease Portfolio

Jazz Pharmaceuticals announced plans to acquire Actio, a rare epilepsy drugmaker, in a deal valued at up to $1.3 billion. The acquisition strengthens Jazz's position in neurological diseases and rare conditions.

Unpacked:

• The deal adds specialized epilepsy treatments to Jazz's existing rare disease portfolio, particularly in neurological disorders.
• The $1.3 billion valuation reflects continued investor confidence in the rare disease market despite broader biotech volatility.
• This acquisition follows industry trends toward consolidation in specialty therapeutic areas with limited competition and high unmet need.

Vertex Competitor Falls Short in Cystic Fibrosis Trial

Sionna Therapeutics' experimental cystic fibrosis drug failed to meet endpoints in a Phase 2/3 trial, effectively removing a potential threat to Vertex Pharmaceuticals' dominant market position. The setback was covered by both BioPharma Dive and STAT News, underscoring its industry significance.

Unpacked:

• The trial failure leaves Vertex's Trikafta franchise facing minimal near-term competition in the lucrative cystic fibrosis market.
• Sionna's pill was designed to offer an alternative mechanism to Vertex's CFTR modulators but failed to demonstrate sufficient efficacy.
• The result highlights the difficulty of challenging established therapies in rare diseases where clinical trial recruitment is limited.

FDA Mandates Transparency for Food Additives

The FDA announced it will require manufacturers to notify the agency when adding substances to the food supply, marking the first such requirement in agency history. The policy change addresses long-standing concerns about the "generally recognized as safe" (GRAS) designation process.

Unpacked:

• Food manufacturers previously could add GRAS substances without any FDA notification, creating potential safety oversight gaps.
• The new requirement aims to improve transparency and allow FDA review of additives before widespread consumer exposure.
• This regulatory shift reflects growing public and political pressure for stricter food safety standards and ingredient disclosure.

The Shortlist

• Vaderis Therapeutics secured $152 million in Series B funding to advance its AKT-targeting drug candidate for hereditary hemorrhagic telangiectasia.

• Bristol Myers Squibb outlined plans for a $2.3 billion manufacturing facility in Houston, expanding its production capacity.

• Tenax Therapeutics saw its heart failure drug levosimendan fail a pivotal Phase 3 trial, complicating the company's narrow FDA approval pathway.

• ITM Radiopharma received an FDA rejection for its neuroendocrine tumor treatment due to manufacturing concerns, delaying a potential Novartis competitor.

• Latigo Biotherapeutics raised nearly $350 million in its IPO to fund development of pain management therapies.